Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol

Nicole M. Brown, Barbara Matthews, Patricia A. Ford

Research output: Contribution to journalReview article

  • 4 Citations

Abstract

High-dose chemotherapy (HDCT) followed by autologous peripheral blood stem cell transplantation (APBSCT) is the standard treatment for multiple myeloma and relapsed or high-risk lymphomas. To avoid bleeding complications and to treat profound anemia posttransplant, as a rule, patients are given transfusions after APBSCT. But Jehovah's Witnesses decline transfusions based on religious convictions, making the treatment of these patients' hematologic malignancies a special challenge. The authors of this report describe a transfusion-free APBSCT protocol with acceptable morbidity and mortality used on 48 Jehovah's Witnesses. Infectious complications due to transfusion are avoided; anemia is managed mainly with prophylactic erythropoierin, IV iron therapy, and volume support; and thrombocytopenia is managed solely with the use of hemostatic agents, vitamin K, and oprelvekin. Only 1 of the 48 patients died because a transfusion was withheld, and only 1 had a major bleed, which resolved upon administration of cryoprecipitate. The experiences gained in treating this patient population suggest that HDCT and APBSCT can be safely performed without the use of blood products.

Original languageEnglish
Pages (from-to)776-780
Number of pages5
JournalCommunity Oncology
Volume3
Issue number12
StatePublished - Dec 2006

Fingerprint

Jehovah's Witnesses
Peripheral Blood Stem Cell Transplantation
Stem Cells
Transplants
Anemia
Drug Therapy
Vitamin K
Hemostatics
Hematologic Neoplasms
Multiple Myeloma
Thrombocytopenia
Lymphoma
Iron
Hemorrhage
Morbidity
Mortality

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol. / Brown, Nicole M.; Matthews, Barbara; Ford, Patricia A.

In: Community Oncology, Vol. 3, No. 12, 12.2006, p. 776-780.

Research output: Contribution to journalReview article

Brown, Nicole M.; Matthews, Barbara; Ford, Patricia A. / Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol.

In: Community Oncology, Vol. 3, No. 12, 12.2006, p. 776-780.

Research output: Contribution to journalReview article

@article{da5e44150a32456bb2e29894db30111e,
title = "Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol",
abstract = "High-dose chemotherapy (HDCT) followed by autologous peripheral blood stem cell transplantation (APBSCT) is the standard treatment for multiple myeloma and relapsed or high-risk lymphomas. To avoid bleeding complications and to treat profound anemia posttransplant, as a rule, patients are given transfusions after APBSCT. But Jehovah's Witnesses decline transfusions based on religious convictions, making the treatment of these patients' hematologic malignancies a special challenge. The authors of this report describe a transfusion-free APBSCT protocol with acceptable morbidity and mortality used on 48 Jehovah's Witnesses. Infectious complications due to transfusion are avoided; anemia is managed mainly with prophylactic erythropoierin, IV iron therapy, and volume support; and thrombocytopenia is managed solely with the use of hemostatic agents, vitamin K, and oprelvekin. Only 1 of the 48 patients died because a transfusion was withheld, and only 1 had a major bleed, which resolved upon administration of cryoprecipitate. The experiences gained in treating this patient population suggest that HDCT and APBSCT can be safely performed without the use of blood products.",
author = "Brown, {Nicole M.} and Barbara Matthews and Ford, {Patricia A.}",
year = "2006",
month = "12",
volume = "3",
pages = "776--780",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "12",

}

TY - JOUR

T1 - Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol

AU - Brown,Nicole M.

AU - Matthews,Barbara

AU - Ford,Patricia A.

PY - 2006/12

Y1 - 2006/12

N2 - High-dose chemotherapy (HDCT) followed by autologous peripheral blood stem cell transplantation (APBSCT) is the standard treatment for multiple myeloma and relapsed or high-risk lymphomas. To avoid bleeding complications and to treat profound anemia posttransplant, as a rule, patients are given transfusions after APBSCT. But Jehovah's Witnesses decline transfusions based on religious convictions, making the treatment of these patients' hematologic malignancies a special challenge. The authors of this report describe a transfusion-free APBSCT protocol with acceptable morbidity and mortality used on 48 Jehovah's Witnesses. Infectious complications due to transfusion are avoided; anemia is managed mainly with prophylactic erythropoierin, IV iron therapy, and volume support; and thrombocytopenia is managed solely with the use of hemostatic agents, vitamin K, and oprelvekin. Only 1 of the 48 patients died because a transfusion was withheld, and only 1 had a major bleed, which resolved upon administration of cryoprecipitate. The experiences gained in treating this patient population suggest that HDCT and APBSCT can be safely performed without the use of blood products.

AB - High-dose chemotherapy (HDCT) followed by autologous peripheral blood stem cell transplantation (APBSCT) is the standard treatment for multiple myeloma and relapsed or high-risk lymphomas. To avoid bleeding complications and to treat profound anemia posttransplant, as a rule, patients are given transfusions after APBSCT. But Jehovah's Witnesses decline transfusions based on religious convictions, making the treatment of these patients' hematologic malignancies a special challenge. The authors of this report describe a transfusion-free APBSCT protocol with acceptable morbidity and mortality used on 48 Jehovah's Witnesses. Infectious complications due to transfusion are avoided; anemia is managed mainly with prophylactic erythropoierin, IV iron therapy, and volume support; and thrombocytopenia is managed solely with the use of hemostatic agents, vitamin K, and oprelvekin. Only 1 of the 48 patients died because a transfusion was withheld, and only 1 had a major bleed, which resolved upon administration of cryoprecipitate. The experiences gained in treating this patient population suggest that HDCT and APBSCT can be safely performed without the use of blood products.

UR - http://www.scopus.com/inward/record.url?scp=33845990591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845990591&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 776

EP - 780

JO - Community Oncology

T2 - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 12

ER -